Sanofi (SNY) Operating Income (2009 - 2026)
Sanofi's (SNY) quarterly Operating Income came in at $1.2 billion in Q2 2026, down 27.06% year-over-year from $1.7 billion in Q2 2025, and down 50.99% quarter-over-quarter from $2.5 billion in Q1 2026.
Analysis
Sanofi (SNY) Operating Income (2009 - 2026) Analysis & Trends
Sanofi has disclosed Operating Income across 18 years of filings, most recently posting $1.2 billion for Q2 2026.
- In Q2 2026, Operating Income fell 27.06% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $6.7 billion (down 21.29% YoY), while the FY2025 annual figure was $7.4 billion, down 5.92% from the prior year.
- Operating Income came in at $1.2 billion for Q2 2026 at Sanofi, down from $2.5 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $8.6 billion in Q3 2025 to a low of -$5.6 billion in Q4 2025.
- Average Operating Income over 5 years is $2.6 billion, with a median of $2.4 billion recorded in 2026.
- The largest YoY upside for Operating Income was 122.04% in 2025 against a maximum downside of 1011.95% in 2025.
- Over 5 years, Operating Income stood at $6.7 billion in 2022, then advanced by 12.01% to $7.5 billion in 2023, then plunged by 91.82% to $612.3 million in 2024, then slumped by 1011.95% to -$5.6 billion in 2025, then jumped by 121.79% to $1.2 billion in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $1.2 billion in Q2 2026, $2.5 billion in Q1 2026, and -$5.6 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 4.27 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -505.13 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 697.90 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 330.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 151.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Bn |
| Mar 31, 2026 | 2.48 Bn |
| Dec 31, 2025 | -5.58 Bn |
| Sep 30, 2025 | 8.63 Bn |
| Jun 30, 2025 | 1.67 Bn |
| Mar 31, 2025 | 2.40 Bn |
| Dec 31, 2024 | 612.31 Mn |
| Sep 30, 2024 | 3.89 Bn |
| Jun 30, 2024 | 1.65 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | 7.49 Bn |
| Sep 30, 2023 | 3.50 Bn |
| Jun 30, 2023 | 2.02 Bn |
| Mar 31, 2023 | 2.64 Bn |
| Dec 31, 2022 | 6.69 Bn |
| Sep 30, 2022 | 2.75 Bn |
| Jun 30, 2022 | 1.53 Bn |
| Mar 31, 2022 | 2.69 Bn |
| Dec 31, 2021 | 7.58 Bn |
| Sep 30, 2021 | 3.58 Bn |